Ind-Swift Laboratories Ltd share price today (on 4 October 2023).

We Provide Best stock tips for Ind-Swift Laboratories Ltd. A1 Intraday Tips is accurate share tips Provider Company in India in Nse market. A1 Intraday Tips, also provide Daily Charts with Nse Share Market current price of Ind-Swift Laboratories Ltd with today performance in nse market. Contact Us for Jackpot Stock tips.

Get Free Stock Tips for Ind-Swift Laboratories Ltd

BSE: 532305 | NSE: INDSWFTLAB | ISIN: INE915B01019 Market Cap: [Rs.Cr.] 209 | Face Value: [Rs.] 10 Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

The company manufactures a range of macrolide antibiotics such as erythromycin, roxithromycin, azithromycin and clarithromycin. Besides this Ind-Swift also manufactures steroids such as betamethasone sodium phosphate, betamethasone valerate and betametInd-Swift Laboratories Ltd is a part of the Ind-swift Group and is based at Chandigarh, India. The company manufactures and sells active pharmaceutical ingredients (API). Their product pipeline consists of 25 products, which includes drugs, which include Clarithromycin (Macrolide antibiotic), Atorvastatin (anticholestrol), Fexofenadine (antihistamine), Clopidogrel (anticholestrol), Nitazoxanide (antidiarrheal), Pioglitazone (antidiabetic), Letrozole and Anastrozole (anticancer), Venlafaxine (antidepressants) and Quetipine and Aripirazole (antipsychotic). The company has one subsidiary namely, Ind-Swift Laboratories Inc in USA.
Ind-Swift Laboratories Ltd was incorporated in the year 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation. Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries. In the year 1997, the company went public and concentrated on the manufacture of Active Pharmaceutical Ingredients (API). In the year 1998-99, they launched two molecules, Clarithromycin and Roxithromycin. Their in-house R&D developed Clarithromycin Granules for the first time in India. In the year 2000, the company developed a new drug namely, Astrovastatin. In addition, they entered into an agreement with eight international pharmaceutical companies to source their requirements for Clarithromycin Fexofenadine Roxithromycin and Candesartan from the company.
During the year 2003-04, the company increased the production capacity of bulk drugs/ intermediates from 81.18 TPA to 120 TPA. In addition, they commissioned the granulation facility as per CGMP standards. They launched four new products namely, Acamprosate (alcohol abstinence), Ezetimibe (anti-hyperlipidemic), Anastrazole (oncology) and Nitazoxanide (anti-diarroheal). In January 2, 2004, the company incorporated a wholly owned subsidiary, namely Ind-Swift Laboratories Inc in USA to strengthen the company's presence in contract research and manufacturing services. In June 2004, the subsidiary company commenced their operations. During the year 2004-05, the company expanded the production capacity of bulk drugs/ intermediates from 120 TPA to 150 TPA. They commissioned waste heat recovery unit to reduce energy costs. They opened and office in China to facilitate the import of raw materials. The company introduced five new products in the market. During the year 2005-06, the company completed and commissioned their new plant at Samba in Jammu & Kashmir to manufacture products for the domestic markets. Also, they set up a new state of the art Research & Development center at Mohali, Punjab with an investment of USD 5 million. They increased the production capacity of bulk drugs/ intermediates by 87.03 TPA to 237.03 TPA.
During the year, the company launched new products namely, Letrozole, Anastrozole (Anti-Cancer) Venlafaxine (Anti-Depressants) Lavofloxacin (Anti-Biotic) Quetipine & Aripirazole (Anti-Pshychotic) in the market. They entered into a joint venture with Farayand Chemi Hakim Co, a private joint stock company registered under the law of Iran to focus on the marketing of the products in Middle East & Iran. During the year 2006-07, the company expanded the production capacity of bulk drugs/ intermediates by 18.85 TPA to 255.88 TPA. In April 2006, the company inaugurated their new manufacturing facilities at Baddi in Himachal Pradesh to manufacture tablets, injectibles and liquids. During the year 2007-08, the company entered into the field of Phytochemicals, where, the company has put to operation a new manufacturing facility to manufacture mint-based products. They increased the production capacity of bulk drugs/ intermediates by 162.30 TPA to 418.18 TPA.
According to the Consolidated - Audited financial statement for the Year of 2012, total net operating revenues increased with 44.51%, from INR 942.01 tens of millions to INR 1,361.28 tens of millions. Operating result increased from INR 149.59 tens of millions to INR 178.04 tens of millions which means 19.02% change. The results of the period increased 2.56% reaching INR 88.9 tens of millions at the end of the period against INR 86.68 tens of millions last year. Return on equity (Net income/Total equity) went from 14.99% to 10.77%, the Return On Asset (Net income / Total Asset) went from 4.99% to 4.28% and the Net Profit Margin (Net Income/Net Sales) went from 9.20% to 6.53% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 168.76% compared to 206.78% of last year.